Chemical Antibody Mimics Inhibit Cadherin-Mediated Cell-Cell Adhesion: A Promising Strategy for Cancer Therapy.
Paulina X Medina RangelElena MoroniFranck MerlierLevi A GheberRazi VagoBernadette Tse Sum BuiKarsten HauptPublished in: Angewandte Chemie (International ed. in English) (2019)
One of the most promising strategies to treat cancer is the use of therapeutic antibodies that disrupt cell-cell adhesion mediated by dysregulated cadherins. The principal site where cell-cell adhesion occurs encompasses Trp2 found at the N-terminal region of the protein. Herein, we employed the naturally exposed highly conserved peptide Asp1-Trp2-Val3-Ile4-Pro5-Pro6-Ile7, as epitope to prepare molecularly imprinted polymer nanoparticles (MIP-NPs) to recognize cadherins. Since MIP-NPs target the site responsible for adhesion, they were more potent than commercially available therapeutic antibodies for inhibiting cell-cell adhesion in cell aggregation assays, and for completely disrupting three-dimensional tumor spheroids as well as inhibiting invasion of HeLa cells. These biocompatible supramolecular anti-adhesives may potentially be used as immunotherapeutic or sensitizing agents to enhance antitumor effects of chemotherapy.
Keyphrases
- cell adhesion
- single cell
- cell therapy
- cancer therapy
- molecularly imprinted
- signaling pathway
- induced apoptosis
- drug delivery
- stem cells
- transcription factor
- cell proliferation
- cell migration
- cystic fibrosis
- young adults
- bone marrow
- high throughput
- mass spectrometry
- oxidative stress
- ionic liquid
- papillary thyroid
- solid phase extraction
- monoclonal antibody